Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lacticaseibacillus rhamnosus CRL 2244 extract
- Development stage
- Preclinical
- Lead developer
- Centro de Referencia para Lactobacilos
- Modality
- Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Lacticaseibacillus rhamnosus CRL 2244 extract is a cell-free conditioned media extract containing secreted metabolites (<3 kDa) from the Lacticaseibacillus rhamnosus CRL 2244 strain. It is being investigated as an antimicrobial and antivirulence agent against multidrug-resistant (MDR) bacterial pathogens, including carbapenem-resistant Acinetobacter baumannii (CRAB), methicillin-resistant Staphylococcus aureus (MRSA), and carbapenemase-producing Klebsiella pneumoniae (KPC). The extract exhibits bactericidal activity, inhibits bacterial adhesion and biofilm formation, and downregulates key virulence-associated genes (such as hla, lukAB, fnbA, and icaA in MRSA) without inducing cytotoxic effects in human serum. It also demonstrates synergistic effects when combined with standard antibiotics like beta-lactams.
- Other names
- CRL 2244 extractCRL2244 extractCRL-2244 extractLacticaseibacillus rhamnosus CRL 2244 cell-free conditioned media extractLacticaseibacillus rhamnosus CRL 2244 secreted metabolitesLcb. rhamnosus CRL 2244 extract
Beyond the preview
Go deeper on Lacticaseibacillus rhamnosus CRL 2244 extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lacticaseibacillus rhamnosus CRL 2244 extract.